• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Defining ‘Specialty Lite’ | Asembia 2024


The GLP-1s and some of the migraine drugs are included in this category of drugs that are priced to cost between $5,000 and $15,000 a year and are dispensed at a retail pharmacies, George Van Antwerp, MBA, a managing director at Deloitte, explains.

George Van Antwerp, MBA, a managing director at Deloitte, spoke with MHE prior to his presentation today at the Asembia 2024 meeting in Las Vegas.

Van Antwerp says "specialty" is a middle-ground of prescription drugs that are priced to cost between $5,000-$15,000 a year.

Some of the migraine medications, the GLP-1s for diabetes and weight loss and second-generation antipsychotics fall into the lite category. They are typically dispensed at a retail pharmacy because they don't require great degrees of special handling or administration, but they are more involved (and more expensive) than most drugs dispensed at retail pharmacies.

Also on the panel joining Van Antwerp for the discussion includes Brian Ellis, head of access and reimbursement, AbbVie; Josh Marsh, vice president and general manager, Cardinal Health Sonexus Access & Patient Support; Ronak Patel, vice president, pharmacy network operations, Asembia; and Jessica Ringena, senior vice president, Hy-Vee.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.